The efficacy of colistin monotherapy versus combination therapy with other antimicrobials against carbapenem-resistant Acinetobacter baumannii ST2 isolates

This study aimed to investigate the efficacy of colistin both alone and in combination with either meropenem or levofloxacin against CRAB clinical isolates. The OXA carbapenemase genes and multilocus sequence typing were detected after 35 CRAB isolates biochemical identification. Then, the minimum inhibitory concentrations, minimum bactericidal concentrations, antibiotic interactions of the test antibiotics, and synergistic effects were determined by the checkerboard method and time-kill assays. The chromosomal gene bla OXA-51-like was detected in all isolates, and bla OXA-23-like and bla OXA-24-like were present in 91.4% and 25.7% of the isolates, respectively. The combination of colistin and meropenem displayed the highest rate of synergy (51.4%) against the 35 isolates, while the colistin-levofloxacin combination showed a higher rate of indifference interaction (22.9%) than that of the colistin-meropenem (8.6%) combination. The synergistic effect of colistin against the CRAB isolates was confirmed. The combination of colistin with meropenem is recommended against CRAB isolates.

[1]  Yong Wang,et al.  Molecular characterization and epidemiology of carbapenem non-susceptible Enterobacteriaceae isolated from the Eastern region of Heilongjiang Province, China , 2018, BMC Infectious Diseases.

[2]  L. Leibovici,et al.  Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. , 2018, The Lancet. Infectious diseases.

[3]  I. Barišić,et al.  Arrival of carbapenem-hydrolyzing-oxacillinases in Acinetobacter baumannii in Bosnia and Herzegovina. , 2018, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[4]  L. Miller,et al.  A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis , 2018, Antimicrobial Agents and Chemotherapy.

[5]  T. Chatsuwan,et al.  In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates. , 2018, Diagnostic microbiology and infectious disease.

[6]  D. O’Callaghan,et al.  New Delhi Metallo-β-Lactamase-Producing Carbapenem-Resistant Enterobacteriacae Isolated From Bronchial Washings. , 2017, Irish medical journal.

[7]  Y. Ye,et al.  Activity of levofloxacin in combination with colistin against Acinetobacter baumannii: In vitro and in a Galleria mellonella model. , 2017, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[8]  O. Cars,et al.  Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments , 2017, Infectious diseases.

[9]  Wen-juan Wei,et al.  Synergy against extensively drug-resistant Acinetobacter baumannii in vitro by two old antibiotics: colistin and chloramphenicol. , 2017, International journal of antimicrobial agents.

[10]  R. Moniri,et al.  Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii , 2017, Iranian journal of microbiology.

[11]  M. Kempf,et al.  Wide spread of OXA-23-producing carbapenem-resistant Acinetobacter baumannii belonging to clonal complex II in different hospitals in Lebanon. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[12]  Y. Cong,et al.  Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model , 2016, PloS one.

[13]  S. Baker,et al.  In vitro activity of colistin in antimicrobial combination against carbapenem-resistant Acinetobacter baumannii isolated from patients with ventilator-associated pneumonia in Vietnam , 2015, Journal of medical microbiology.

[14]  Yuemei Lu,et al.  Transition of bla OXA-58-like to bla OXA-23-like in Acinetobacter baumannii Clinical Isolates in Southern China: An 8-Year Study , 2015, PloS one.

[15]  J. Lacherade,et al.  Community-acquired Acinetobacter baumannii pneumonia. , 2015, Medecine et maladies infectieuses.

[16]  P. Nordmann,et al.  Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. , 2015, International journal of antimicrobial agents.

[17]  C. Nikam,et al.  Molecular characterization of carbapenem-resistant Enterobacteriaceae at a tertiary care laboratory in Mumbai , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[18]  E. Giamarellos‐Bourboulis,et al.  Time–kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[19]  G. Signoriello,et al.  Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Russell E. Lewis,et al.  Synergistic Activity of Colistin plus Rifampin against Colistin-Resistant KPC-Producing Klebsiella pneumoniae , 2013, Antimicrobial Agents and Chemotherapy.

[21]  Rui Wang,et al.  Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. , 2012, The Journal of antimicrobial chemotherapy.

[22]  P. Nordmann,et al.  Carbapenem resistance in Enterobacteriaceae: here is the storm! , 2012, Trends in molecular medicine.

[23]  K. Kaye,et al.  Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  P. Nordmann,et al.  Worldwide Dissemination of the blaOXA-23 Carbapenemase Gene of Acinetobacter baumannii1 , 2010, Emerging infectious diseases.

[25]  I. Gould,et al.  Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. , 2010, The Journal of antimicrobial chemotherapy.

[26]  G. French,et al.  Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. , 2006, The Journal of antimicrobial chemotherapy.

[27]  M. Kaufmann,et al.  The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. , 2006, FEMS microbiology letters.

[28]  P. Patsalos,et al.  The Importance of Drug Interactions in Epilepsy Therapy , 2002, Epilepsia.